116 related articles for article (PubMed ID: 29626126)
1. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Tsai CY; Sun S; Zhang H; Local A; Su Y; Gross LA; Rice WG; Howell SB
Mol Cancer Ther; 2018 Jun; 17(6):1167-1176. PubMed ID: 29626126
[TBL] [Abstract][Full Text] [Related]
2. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.
Local A; Zhang H; Benbatoul KD; Folger P; Sheng X; Tsai CY; Howell SB; Rice WG
Mol Cancer Ther; 2018 Jun; 17(6):1177-1186. PubMed ID: 29626127
[TBL] [Abstract][Full Text] [Related]
3. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
4. Modeling Therapy Resistance in
Dréan A; Williamson CT; Brough R; Brandsma I; Menon M; Konde A; Garcia-Murillas I; Pemberton HN; Frankum J; Rafiq R; Badham N; Campbell J; Gulati A; Turner NC; Pettitt SJ; Ashworth A; Lord CJ
Mol Cancer Ther; 2017 Sep; 16(9):2022-2034. PubMed ID: 28619759
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
6. Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Carbajosa S; Pansa MF; Paviolo NS; Castellaro AM; Andino DL; Nigra AD; García IA; Racca AC; Rodriguez-Berdini L; Angiolini V; Guantay L; Villafañez F; Federico MB; Rodríguez-Baili MC; Caputto BL; Drewes G; Madauss KP; Gloger I; Fernandez E; Gil GA; Bocco JL; Gottifredi V; Soria G
Clin Cancer Res; 2019 Jul; 25(13):4049-4062. PubMed ID: 30890549
[TBL] [Abstract][Full Text] [Related]
7. Inducing synthetic lethality using PARP inhibitors.
Boss DS; Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
9. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
10. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
Tacconi EM; Badie S; De Gregoriis G; Reisländer T; Lai X; Porru M; Folio C; Moore J; Kopp A; Baguña Torres J; Sneddon D; Green M; Dedic S; Lee JW; Batra AS; Rueda OM; Bruna A; Leonetti C; Caldas C; Cornelissen B; Brino L; Ryan A; Biroccio A; Tarsounas M
EMBO Mol Med; 2019 Jul; 11(7):e9982. PubMed ID: 31273933
[TBL] [Abstract][Full Text] [Related]
11. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
12. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
13. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
15. 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors.
Cincinelli R; Musso L; Merlini L; Giannini G; Vesci L; Milazzo FM; Carenini N; Perego P; Penco S; Artali R; Zunino F; Pisano C; Dallavalle S
Bioorg Med Chem; 2014 Feb; 22(3):1089-103. PubMed ID: 24398383
[TBL] [Abstract][Full Text] [Related]
16. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
17. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
18. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
19. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
20. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]